Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 3
2007 3
2008 3
2009 3
2010 8
2011 5
2012 6
2013 9
2014 10
2015 14
2016 15
2017 11
2018 18
2019 19
2020 19
2021 19
2022 20
2023 5

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31471412

179 results

Results by year

Filters applied: . Clear all
Page 1
Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
Kawaguchi K, Nakano K, Urasaki T, Fukuda N, Taira S, Ono M, Tomomatsu J, Nishizawa M, Ae K, Matsumoto S, Takahashi S. Kawaguchi K, et al. In Vivo. 2019 Sep-Oct;33(5):1609-1614. doi: 10.21873/invivo.11644. In Vivo. 2019. PMID: 31471412 Free PMC article.
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Grignani G, et al. Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11. Lancet Oncol. 2018. PMID: 30217671 Free article. Clinical Trial.
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Grosso F, D'Ambrosio L, Zucchetti M, Ibrahim T, Tamberi S, Matteo C, Rulli E, Comandini D, Palmerini E, Baldi GG, DeCensi A, Bergaglio M, Marra D, Marchesi E, Siri G, D'Incalci M, Grignani G. Grosso F, et al. Cancer. 2020 Nov 1;126(21):4726-4734. doi: 10.1002/cncr.33120. Epub 2020 Aug 4. Cancer. 2020. PMID: 32749681 Free article. Clinical Trial.
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, Schuetze S, Li J, Aymes A, Demetri GD. Samuels BL, et al. Ann Oncol. 2013 Jun;24(6):1703-9. doi: 10.1093/annonc/mds659. Epub 2013 Feb 5. Ann Oncol. 2013. PMID: 23385197 Free article. Clinical Trial.
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Jones RL, et al. Ann Oncol. 2018 Sep 1;29(9):1995-2002. doi: 10.1093/annonc/mdy253. Ann Oncol. 2018. PMID: 30084934 Free PMC article. Clinical Trial.
179 results